Table 1: Clinical data of the study population before the start of anti-retroviral therapy.

– Normal Value Range Median Interquartile Range
Lumbar BMD (g/cm2) – 0.919 [0.856-1.054]
Lumbar T-score – -1.10 [-1.60-0.10]
Lumbar Z-score – -0.500 [-0.900-0.200]
Femoral neck BMD (g/cm2) – 0.759 [0.711-0.843]
Femoral T-score – -0.800 [-1.20--0.188]
Femoral Z-score – -0.350 [-0.800-0.300]
Age (years) – 37.0 [31.3-49.0]
BMI – 22.4 [19.6-24.1]
CD4 (/μL) – 275 [125-347]
HIV RNA copies (×103) – 41.0 [21.0-101]
AST (IU/L) [13-30] 24.0 [20.0-29.5]
ALT (IU/L) [10-42] 21.0 [15.0-29.8]
ALP (IU/L) [124-222] 262 [202-282]
Cre (mg/dL) [0.65-1.07] 0.800 [0.725-0.890]
Ca (mg/dL) [8.8-10.1] 8.90 [8.63-9.20]
P (mg/dL) [2.5-4.5] 3.60 [3.30-3.80]
1.25VitD (pg/ml) [20-60] 46.7 [37.7-55.0]
25OHVitD (pg/ml) [7-41] 18.5 [14.5-26.0]
FGF23(pg/ml) [10-50] 43.0 [37.1-55.0]
PTHin(pg/ml) [10.3-65.9] 39.0 [31.0-49.0]
BAP (μg/L) [3.7-20.9] 11.8 [9.40-15.0]
NTx/Cr (nmolBCE/mmolCr) [13.0-66.2] 32.5 [28.7-43.8]
Smoking (cases) – 13 (41.9%)
HCV infection (cases) – 1 (3.23%)

BMD: Bone mineral density, BMI: body mass index, AST: Aspartate transaminase, ALT: Alanine aminotransferase, Ca: Serum calcium, P: Serum phosphorus, 1.25VitD: serum 1.25-dihydroxyvitamin D3, 25OHvitD: serum 25-hydroxyvitamin D, FGF23: Serum fibroblast growth factor 23, PTHin: Serum intact parathyroid hormone, BAP: Serum bone-specific alkaline phosphatase, NTx/Cr: Urinary N- terminal telopeptide/creatinine.